We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which sections of the website you find most interesting and useful. See our Cookie Policy for more information.
These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.
Enables storage (such as cookies) related to analytics e.g. visit duration.
Enables storage related to personalization e.g. video recommendations
Enables storage (such as cookies) related to advertising.
Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually.
Prior to Proactive, Ian helped lead the business output at the Daily... Read more
About the publisher
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists.
Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth.
We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors.
The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies.
Use of technology
Proactive has always been a forward looking and enthusiastic technology adopter.
Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows.
Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.
You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.
You understand...
Do Motif Bio's US rivals provide a value benchmark for the UK drug developer?
Published: 14:57 15 Nov 2017 GMT
The company's NASDAQ listing could be key to driving up the company's value
Motif Bio Plc (LON:MTFB, NASDAQ:MTFB) has come a long way since it took its AIM bow back in April 2015.
It has manufactured clinical trial supplies of its lead drug, iclaprim, completed two successful phase III clinical trial on the next-generation antibiotic and, crucially, raised US$110mln.The last piece of the financing jigsaw was put in place on Wednesday when it unveiled US$20mln of debt funding.
This should see the drug developer through that tricky period in which iclaprim undergoes regulatory scrutiny by the US Food & Drug Administration (FDA).
How Motif stacks up
Yet Motif, market capitalisation US$130mln, probably isn’t receiving the market recognition its progress deserves.
Benchmarking the firm brings this point into sharp relief.
Take Paratek Pharmaceuticals (NASDAQ:PRTK). It has an antibiotic at a similar stage of development to Motif’s iclaprim targeting the same patient group – those with acute bacterial skin and skin structure infection (ABSSSI).
More to the point, it is valued at more than US$562mln. In that comparator group are also Achaogen (market cap US$503mln), Tetraphase (US$308mln) and Nabriva (US$205mln).
All are listed on the NASDAQ, which has a far greater understanding of the life sciences sector, along with a deeper pool of capital to back up and coming businesses of Motif’s ilk.
Shackles coming off
Now, followers of the UK firm will correctly point out that Motif also has a quote of the US tech market; however, the company has been subject to “certain restrictions” in the 11 months it has been a NASDAQ constituent, chief executive Graham Lumsden said.
The shackles come off next month, he added. “We will get much better access to the US and an investor and analyst base that understands and values the space,” he told Proactive.
This coincides with what is expected to be a pivotal period in the company’s history as it formally makes its new drug application (NDA) to the FDA in the first quarter of next year.
While certainly not a slam dunk, given the US regulator’s sometimes ruthless approach to giving sign-off, Lumsden is confident.
“I think it is in the public domain: if you are submitting an NDA you go through some pre-NDA processes. It is looking great,” he said.
Orphan designation
iclaprim has orphan designation for use in cystic fibrosis patients with lung infections and is undergoing phase II trials as a treatment for hospital-acquire pneumonia with results from the study said to be “imminent”.
There may be an opportunity to deploy the drug for other serious bacterial ailments outside the scope of an eventual sign off ABSSSI, particularly with the advent of the 21st Cures Act in the US.
Lumsden says the Act is “important to us as for the first time it allows off-label promotion”.
So what else might put a bottle rocket under the Motif share price?
M&A activity in this very specialised field of drug development has been noticeable by its absence in recent years, although industry watchers said they are starting to see faint stirrings.
Team up?
More likely, the companies developing the next batch of antibiotics will team up.
Analysts point out most of these businesses are single-product operations heading into an expensive commercial phase of development.
By pooling their efforts the cost of R&D and, crucially expenses incurred selling products to hospitals in the US, fall dramatically.
It will be interesting to see how activity in the sector plays out, where Motif sits when the tectonic plates start moving and how its significant potential might be valued.
Accesso Technology Group PLC (AIM:ACSO, OTC:LOQPF) chief executive Steve Brown joins Proactive's Stephen Gunnion with details of a significant partnership with Saudi Entertainment Ventures (SEVEN).
Brown noted the collaboration highlights accesso's strategy to grow its global footprint,...